SCHEMBL2181779

SCHEMBL2181779

Cc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 10/20 1.00
SIRT1 Q96EB6 1/20 1.00
KDM4C Q9H3R0 7/20 0.80
RAF1 P04049 2/20 0.80
MAP2K1 Q02750 2/20 0.80
KDM4E B2RXH2 1/20 0.80
MEN1 O00255 1/20 0.80
NPC1 O15118 1/20 0.80
S1PR2 O95136 1/20 0.80
S1PR4 O95977 1/20 0.80
ALDH1A1 P00352 1/20 0.80
LMNA P02545 1/20 0.80
POLB P06746 1/20 0.80
MAPT P10636 1/20 0.80
THRB P10828 1/20 0.80
HPGD P15428 1/20 0.80
S1PR1 P21453 1/20 0.80
MAPK1 P28482 1/20 0.80
CTNNB1 P35222 1/20 0.80
HTT P42858 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179691 0.89 KDM4C (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL2180580 0.89 TDP2 (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL2183740 0.88 TDP2 (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL3472993 0.87 KDM4C (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL15032641 0.86 TDP2 (0.76) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL2186422 0.86 KDM4C (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL2183454 0.86 TDP2 (0.76) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL3472472 0.85 TDP2 (1.00) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL15032643 0.84 TDP2 (0.84) TDP2SIRT1KDM4CRAF1MAP2K1
SCHEMBL2182276 0.84 TDP2 (0.72) TDP2SIRT1KDM4CRAF1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010072807-A2 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2010-07-01 WO claimed
US-9073941-B2 Compounds and methods for treating tuberculosis infection ACADEMIA SINICA (TW) 2015-07-07 US disclosed
US-9073941-B2 Compounds and methods for treating tuberculosis infection ACADEMIA SINICA (TW) 2015-07-07 US disclosed
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION ACADEMIA SINICA (TW) 2013-06-20 US disclosed
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION ACADEMIA SINICA (TW) 2013-06-20 US disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed
WO-2010072807-A2 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158037-A1 COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION TALDO1, PGD, DLD TDP2 3811/4885SIRT1 115/4885KDM4C 1158/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR TDP2 685/4885SIRT1 3317/4885KDM4C 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.